With new 500L and 2,000L options, the enhanced X-platform enables seamless scale-up from 50L, helping researchers boost efficiency, cut costs, and meet the rising demand for clinical and commercial biomanufacturing.
-
X-platform bioreactors are designed to help navigate challenges by combining reliability, scalability, and flexibility in one solution
-
Scientists and researchers can seamlessly scale from 50L to 2 000L to meet growing demand for clinical trials and regulatory approved products
As researchers and scientists work to discover the next generation of advanced therapeutics, Cytiva is expanding the Xcellerex X-platform portfolio to meet their growing needs with the addition of 500L and 2 000L bioreactors. The X-platform is a reliable and flexible single-use system designed to increase operational efficiencies and production capacity, while helping to lower costs, reduce risks, and bring life-changing therapeutics to the next clinical milestone faster.
Ludovic Brellier, President of Hardware Solutions, Cytiva, says: “Our customers need speed and flexibility to develop advanced therapeutics. The expansion of Cytiva’s Xcellerex X-platform portfolio and its additional features will help our customers scale their operations more efficiently. The design and functionality of the hardware, biocontainers and software will allow our customers to safely manufacture life changing therapeutics faster.”
Why the X-Platform is different
The X-platform bioreactor portfolio was designed to meet the process needs of early-stage clinical researchers all the way through to commercial manufacturing. Customers can easily scale from 50L to 2 000L and while also reducing the time spent optimizing. Additional features include:
-
An infrared-based camera that provides accurate detection of foam appearing in the process, allowing for early, automated intervention.
-
Working height management of exhaust filters and heaters designed to simplify filter changes and minimize the need for manipulations at height.
-
Quick and easy “off-the shelf” bag configuration and installation which helps reduce the risk of error. A rigid base construction ensures consistent installation of the single-use bioreactor bag, minimizing the risk of batch failure
History of Xcellerex
Xcellerex single-use technologies were launched more than 20 years ago and have played a significant role in the development of protein-based therapeutics, such as monoclonal antibodies (mAbs). The technology is now playing a critical role in the development of advanced therapeutics, such as cell and gene therapies, mRNA vaccines, and antibody drug conjugates.
